Hostname: page-component-74656f9884-2dmjx Total loading time: 0 Render date: 2026-11-08T06:44:15.986Z Has data issue: false hasContentIssue false

Assessing the impact of health technology assessment in the Netherlands

Published online by Cambridge University Press:  04 July 2008

Wija J. Oortwijn
Affiliation:
ECORYS Nederland BV
Stephen R. Hanney
Affiliation:
Brunel University
Andreas Ligtvoet
Affiliation:
Delft University of Technology
Stijn Hoorens
Affiliation:
RAND Europe Cambridge Ltd.
Steven Wooding
Affiliation:
RAND Europe Cambridge Ltd.
Jonathan Grant
Affiliation:
RAND Europe Cambridge Ltd.
Martin J. Buxton
Affiliation:
Brunel University
Lex M. Bouter
Affiliation:
VU University Amsterdam
Rights & Permissions [Opens in a new window]

Abstract

Objectives: Investments in health research should lead to improvements in health and health care. This is also the remit of the main HTA program in the Netherlands. The aims of this study were to assess whether the results of this program have led to such improvements and to analyze how best to assess the impact from health research.

Methods: We assessed the impact of individual HTA projects by adapting the “payback framework” developed in the United Kingdom. We conducted dossier reviews and sent a survey to principal investigators of forty-three projects awarded between 2000 and 2003. We then provided an overview of documented output and outcome that was assessed by ten HTA experts using a scoring method. Finally, we conducted five case studies using information from additional dossier review and semistructured key informant interviews.

Results: The findings confirm that the payback framework is a useful approach to assess the impact of HTA projects. We identified over 101 peer reviewed papers, more than twenty-five PhDs, citations of research in guidelines (six projects), and implementation of new treatment strategies (eleven projects). The case studies provided greater depth and understanding about the levels of impact that arise and why and how they have been achieved.

Conclusions: It is generally too early to determine whether the HTA program led to actual changes in healthcare policy and practice. However, the results can be used as a baseline measurement for future evaluation and can help funding organizations or HTA agencies consider how to assess impact, possibly routinely. This, in turn, could help inform research strategies and justify expenditure for health research.

Information

Type
GENERAL ESSAYS
Copyright
Copyright © Cambridge University Press 2008
Figure 0

Figure 1. Schematic diagram of the payback model. The model serves to indicate a series of stages that help to organize payback assessments: Stage 0: Topic/Issue Identification involves the generation of the original ideas for the research; Interface A: Project Specification and Selection involves the development of research proposals and the (peer) review process; Stage 1: Inputs to research focus on financial inputs, but also expertise of the research team and knowledge base of the research team; Stage 2: Research Processes concern how the research was conducted and any difficulties encountered in patient inclusion, appropriateness of methods, involvement of potential users, and so on; Stage 3: Primary Outputs from Research relate to knowledge production, mainly publications; Interface B: Dissemination reflects the procedure at the end of a study whereby the findings are disseminated to the policymakers and more widely (e.g., by presentations); Stage 4: Secondary Outputs includes a wide variety of items such as reimbursement decisions by the Ministry of Health; citing of the findings in a clinical guideline from a national or local professional group; or inclusion of the findings in a contract or in a document from an audit, an inspectorate or an evaluative body; Stage 5: Adoption by Practitioners and Public deals with behavioral change that is necessary to implement the findings of the research into practice to result in final outcomes. Examples are adoption of a new surgical technique that appeared to be cost-effective or introduction of a new pharmaceutical on the market; Stage 6: Final Outcomes are seen as the ultimate goal of the research. For health research this goal involves improved public health (or quality of life) and broader economic benefits. Source: (10).

Figure 1

Table 1. Scoring Scales Payback Categories

Figure 2

Table 2. Summary of Research Payback of the Subsidy Rounds Considered

Figure 3

Table 3. Different Measures of Disagreement for Each Payback Criterion

Figure 4

Figure 2. Average score per subsidy round, first scoring. KP, Knowledge Production; RTCB, Research Benefits; IP, Informing Policy; CHP, Changing Health Practice; BH, Broader Impact on Health.